UK first to approve CRISPR treatments for diseases: what you need to know

The landmark decision could transform the treatment of sickle-cell disease and β-thalassaemia — but the technology is expensive. The landmark decision could transform the treatment of sickle-cell disease and β-thalassaemia — but the technology is expensive.

Related Keywords

Massachusetts ,United States ,Boston ,United Kingdom ,Switzerland ,Kay Davies ,Simon Waddington At University College London ,Drug Administration ,David Rueda At Imperial College London ,United Kingdom Science Media Centre ,Science Photo Library ,University Of Oxford ,European Medicines Agency ,Vertex Pharmaceuticals ,Regulatory Agency ,Science Photo ,United Kingdom Science Media ,Nobel Prize ,David Rueda ,Imperial College London ,Simon Waddington ,University College London ,